Primary cutaneous B-cell lymphoma: A single-center 5-year experience

Simple item page
dc.contributor.authorJacob, Linu Abrahamen_US
dc.contributor.authorAsati, Vikasen_US
dc.contributor.authorLakshmaiah, KCen_US
dc.contributor.authorBabu, K Govinden_US
dc.contributor.authorLokanatha, Dasappaen_US
dc.contributor.authorBabu, Suresh MCen_US
dc.contributor.authorKN, Lokeshen_US
dc.contributor.authorAH, Rudreshen_US
dc.contributor.authorLK, Rajeeven_US
dc.contributor.authorNikita J Mulchandanien_US
dc.contributor.authorAnand, Abhisheken_US
dc.contributor.authorKoppaka, Deepaken_US
dc.contributor.authorMysore, Suma Narayanaen_US
dc.date.accessioned2020-01-02T06:27:59Z
dc.date.available2020-01-02T06:27:59Z
dc.date.issued2018-04
dc.description.abstractBACKGROUND: Skin is the second most common site for extranodal non-Hodgkin's lymphoma (NHL). Most primary cutaneous NHLs are of T-cell origin (70%). Primary cutaneous B-cell lymphoma (PCBCL) is a rare entity. MATERIALS AND METHODS: Patients diagnosed with PCBCL between January 2012 and July 2017 at our center were retrospectively analyzed. RESULTS: Eight patients of PCBCL were diagnosed. Three patients (37.5%) were males while 5 patients (62.5%) were females. The median age at diagnosis was 45 years (range, 18–60 years). Scalp was the most common site of involvement (50% of the patients). Diffuse large B-cell lymphoma (DLBCL) was the most common histology (63%), with leg-type DLBCL diagnosed in 1 patient. Two patients had primary cutaneous follicle center lymphoma, whereas the remaining 1 patient had precursor B-lymphoblastic lymphoma. All 5 DLBCL cases were treated with CHOP chemotherapy, and rituximab was given to 3 patients. Of the primary cutaneous follicle center lymphomas, 1 patient with stage II disease was treated with CHOP and is alive without recurrence for the past 5 years, whereas the other patient is on observation alone. The patient with precursor B-lymphoblastic lymphoma was started on MCP-841 protocol; however, the patient did not complete the treatment and died after 11 months. CONCLUSIONS: PCBCL is a heterogeneous group of diseases and dividing them into subtypes, based on morphology and immunophenotype, has therapeutic implications.en_US
dc.identifier.affiliationsDepartment of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, Indiaen_US
dc.identifier.citationJacob Linu Abraham, Asati Vikas, Lakshmaiah KC, Babu K Govind, Lokanatha Dasappa, Babu Suresh MC, KN Lokesh, AH Rudresh, LK Rajeev, Nikita J Mulchandani, Anand Abhishek, Koppaka Deepak, Mysore Suma Narayana. Primary cutaneous B-cell lymphoma: A single-center 5-year experience. Indian Journal of Cancer. 2018 Apr; 55(2): 134-136en_US
dc.identifier.issn0019-509X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/190334
dc.languageenen_US
dc.publisherIndian Cancer Societyen_US
dc.relation.issuenumber2en_US
dc.relation.volume55en_US
dc.source.urihttps://dx.doi.org//10.4103/ijc.IJC_418_17en_US
dc.titlePrimary cutaneous B-cell lymphoma: A single-center 5-year experienceen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijoc2018v55n2p134.pdf
Size:
953.37 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Cancer